Sucampo Pharmaceuticals, Inc. (SCMP) Trading Up 1.4%
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was up 1.4% during mid-day trading on Monday . The company traded as high as $10.55 and last traded at $10.70. Approximately 315,761 shares changed hands during trading, a decline of 35% from the average daily volume of 486,611 shares. The stock had previously closed at $10.55.
Several brokerages have recently weighed in on SCMP. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Leerink Swann began coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $15.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $16.50.
The firm has a market cap of $495.52, a P/E ratio of 7.23, a PEG ratio of 3.27 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. Sucampo Pharmaceuticals’s revenue was up 5.9% compared to the same quarter last year. research analysts expect that Sucampo Pharmaceuticals, Inc. will post 1.08 EPS for the current year.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jason Patrick Meyenburg acquired 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was purchased at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now owns 30,228 shares of the company’s stock, valued at $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in SCMP. NEA Management Company LLC bought a new position in Sucampo Pharmaceuticals in the second quarter worth approximately $13,214,000. Rubric Capital Management LP bought a new position in Sucampo Pharmaceuticals in the second quarter worth approximately $6,068,000. Vanguard Group Inc. grew its stake in Sucampo Pharmaceuticals by 48.9% in the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after purchasing an additional 478,226 shares in the last quarter. Prudential Financial Inc. grew its stake in Sucampo Pharmaceuticals by 871.6% in the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after purchasing an additional 368,090 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after purchasing an additional 190,292 shares in the last quarter. 55.76% of the stock is currently owned by institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.